Related Experiment Video

Updated: Aug 2, 2025

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

5.8K

Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions

Tiffany Dong1, Ben Alencherry1, Susan Ospina1

  • 1Section of Cardiovascular Imaging, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA.

Drug Design, Development and Therapy
|April 17, 2023
PubMed

Insights

Mavacamten, a novel cardiac myosin inhibitor, effectively reduces left ventricular outflow tract obstruction and alleviates symptoms in hypertrophic cardiomyopathy (HCM) patients, potentially delaying invasive procedures.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Hypertrophic cardiomyopathy (HCM) is characterized by abnormal left ventricular hypertrophy.
  • Common symptoms include chest pain, dyspnea, and syncope, often due to outflow tract obstruction.

Purpose of the Study:

  • To review the pharmacology and clinical trial data of mavacamten.
  • To provide guidance on integrating mavacamten into clinical practice for HCM management.
  • To discuss emerging therapies for HCM.

Main Methods:

  • Review of pharmacological properties of mavacamten.
  • Analysis of clinical trial data for mavacamten efficacy and safety.
  • Discussion of current and emerging treatment strategies for HCM.

Main Results:

  • Mavacamten demonstrated significant improvement in obstruction measures.
  • Patients experienced notable symptom relief, allowing deferral of invasive treatments.
  • The drug's pharmacology and clinical application are detailed.

Conclusions:

  • Mavacamten represents a significant advancement in pharmacological treatment for obstructive HCM.
  • Clinical data support its role in improving patient outcomes and quality of life.
  • Further research into emerging HCM therapies is ongoing.

Keywords:
EXPLORER HCMVALOR HCMhypertrophic cardiomyopathymavacamtenseptal reduction therapy

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.2K
Mechanical Control of Relaxation Using Intact Cardiac Trabeculae07:51

Mechanical Control of Relaxation Using Intact Cardiac Trabeculae

Published on: February 17, 2023

1.3K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
18
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
20
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
13
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
26
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
13
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
21